[TTF-1-negative lung adenocarcinoma: special features of systemic treatment].
Nikolaj FrostMartin ReckPublished in: Pneumologie (Stuttgart, Germany) (2023)
The identification of biomarker-adjusted treatments has revolutionized the treatment landscape of metastatic lung cancer and improved survival for a relevant share of patients with actionable genomic alterations and those benefiting from checkpoint inhibitors (CPI). Given a clear correlation between the expression of "programmed death ligand 1" (PD-L1) and treatment efficacy of CPI, immunochemotherapy is used in patients with a PD-L1 expression <50%. The lower the PD-L1 expression, the more important is the chemotherapy backbone. For lung adenocarcinoma, there is currently a choice between pemetrexed- and taxane-based regimens. Retrospective data suggested superior survival using taxane-based treatment for patients negative for "thyroid transcription factor 1". A prospective randomized clinical trial is underway to verify this hypothesis.
Keyphrases
- small cell lung cancer
- transcription factor
- squamous cell carcinoma
- poor prognosis
- newly diagnosed
- machine learning
- clinical trial
- dna damage
- long non coding rna
- gene expression
- electronic health record
- diffuse large b cell lymphoma
- chronic kidney disease
- ejection fraction
- big data
- replacement therapy
- artificial intelligence
- copy number
- metastatic breast cancer
- deep learning
- rectal cancer